Please login to the form below

Not currently logged in
Email:
Password:

Boehringer-Lilly win expanded European licence for Trajenta

Type 2 diabetes drug approved as add-on to insulin in adults

Boehringer Ingelheim Lilly Trajenta linagliptin

European regulators have approved a new indication for Boehringer Ingelheim and Lilly's Trajenta (linagliptin) that will allow it to be used in combination with insulin to treat adults with type 2 diabetes.

The approval means Trajenta is now indicated for use in combination with insulin with or without metformin, when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

This brings it into line with its fellow dipeptidyl peptidase-4 (DPP-4) inhibitors AstraZeneca and BMS' Onglyza (saxagliptin) and Januvia (sitagliptin), Merck & Co's sector-leading drug.

Prof Klaus Dugi, corporate senior vice president medicine at Boehringer Ingelheim, said: “We are delighted that approval has been granted for the use of linagliptin as an add-on to insulin in adults with type 2 diabetes.

“This expanded indication shows that linagliptin is an effective treatment for patients at various stages of type 2 diabetes.”

Trajenta's latest approval was based on trials showing that after 24 weeks, adding the drug to insulin produced better glucose control than insulin alone, without an additional risk of hypoglycaemia.

Trajenta is the lead product in the diabetes alliance Boehringer and Lilly formed last year and the drug was first approved in Europe last August in combination with metformin and metformin plus sulphonylurea. It also has a licence as a monotherapy in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate.

Trajenta works by increasing the level of hormones that stimulate the release of insulin after a meal by blocking the enzyme dipeptidyl peptidase-4 (DPP-4).

Although not the first of the DPP-4 inhibitors to be approved, it is the first to be licensed at one dosage strength (5 mg, once daily), with no dose adjustment necessary in patients with kidney or liver impairment.

Boehringer and Lilly will be hoping to build on this advantage with their follow-up product Jentadueto, which combines Trajenta's active ingredient linagliptin with metformin and was approved in Europe over the summer.

29th October 2012

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
inVentiv Health Communications Europe

Wherever you are, turn to Junction 11 Whatever the communication vehicle and whether your brand is at the beginning of...

Latest intelligence

Online Physician Communities
M3 and partners win Digital Sales Aid Award
Wins for campaign to overcome limited doctor engagement with pharma-owned websites...
UK Customer Experience Awards 2014 Highlights
Stephanie Hall, Managing Director at Uptake Strategies, attended this year’s cross-industry UK Customer Experience Awards as a member of the judging panel for Business Transformation....
McCann3-thumb.jpg
The heart of the matter - Part Three
Is pharma doing enough to maximise real world evidence?...